Norepinephrine transporter in major depressive disorder: A PET study

Sho Moriguchi, Makiko Yamada, Harumasa Takano, Tomohisa Nagashima, Keisuke Takahata, Keita Yokokawa, Takehito Ito, Tatsuya Ishii, Yasuyuki Kimura, Ming Rong Zhang, Masaru Mimura, Tetsuya Suhara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: The norepinephrine transporter hasbeen suggested to play a crucial role in major depressive disorder. However, norepinephrine transporter availability in major depressive disorder and its role with clinical symptoms are not known. The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms. Method: The present research was a cross-sectional study in which 19 patients with major depressive disorder and 19 age- and sex-matched healthy comparison subjects underwent positron emission tomography scanning to evaluate the norepinephrine transporter availability measured by the radioligand (S,S)-[18F]FMeNER-D2. Norepinephrine transporter availability in the thalamus and its subregions was quantified in terms of nondisplaceable binding potential (BPND). The authors also analyzed the association between norepinephrine transporter availability and clinical symptoms. Results: Compared with healthy subjects, patients with major depressive disorder showed 29.0% higher BPND values in the thalamus and, in particular, 28.2% higher values in the thalamic subregion anatomically connected to the prefrontal cortex. Elevated norepinephrine transporter availability in the thalamus in patients was positively correlated with attention, as measured by the Trail Making Test, part A. Conclusions: These findings revealed altered norepinephrine transmission in patients with major depressive disorder, suggesting that this alteration could be related to attention in this patient population.

Original languageEnglish
Pages (from-to)36-41
Number of pages6
JournalAmerican Journal of Psychiatry
Volume174
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
Major Depressive Disorder
Thalamus
Healthy Volunteers
Trail Making Test
Prefrontal Cortex
Positron-Emission Tomography
Norepinephrine
Cross-Sectional Studies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Moriguchi, S., Yamada, M., Takano, H., Nagashima, T., Takahata, K., Yokokawa, K., ... Suhara, T. (2017). Norepinephrine transporter in major depressive disorder: A PET study. American Journal of Psychiatry, 174(1), 36-41. https://doi.org/10.1176/appi.ajp.2016.15101334

Norepinephrine transporter in major depressive disorder : A PET study. / Moriguchi, Sho; Yamada, Makiko; Takano, Harumasa; Nagashima, Tomohisa; Takahata, Keisuke; Yokokawa, Keita; Ito, Takehito; Ishii, Tatsuya; Kimura, Yasuyuki; Zhang, Ming Rong; Mimura, Masaru; Suhara, Tetsuya.

In: American Journal of Psychiatry, Vol. 174, No. 1, 01.01.2017, p. 36-41.

Research output: Contribution to journalArticle

Moriguchi, S, Yamada, M, Takano, H, Nagashima, T, Takahata, K, Yokokawa, K, Ito, T, Ishii, T, Kimura, Y, Zhang, MR, Mimura, M & Suhara, T 2017, 'Norepinephrine transporter in major depressive disorder: A PET study', American Journal of Psychiatry, vol. 174, no. 1, pp. 36-41. https://doi.org/10.1176/appi.ajp.2016.15101334
Moriguchi S, Yamada M, Takano H, Nagashima T, Takahata K, Yokokawa K et al. Norepinephrine transporter in major depressive disorder: A PET study. American Journal of Psychiatry. 2017 Jan 1;174(1):36-41. https://doi.org/10.1176/appi.ajp.2016.15101334
Moriguchi, Sho ; Yamada, Makiko ; Takano, Harumasa ; Nagashima, Tomohisa ; Takahata, Keisuke ; Yokokawa, Keita ; Ito, Takehito ; Ishii, Tatsuya ; Kimura, Yasuyuki ; Zhang, Ming Rong ; Mimura, Masaru ; Suhara, Tetsuya. / Norepinephrine transporter in major depressive disorder : A PET study. In: American Journal of Psychiatry. 2017 ; Vol. 174, No. 1. pp. 36-41.
@article{8e0f99887c134d49a9c91b112478f536,
title = "Norepinephrine transporter in major depressive disorder: A PET study",
abstract = "Objective: The norepinephrine transporter hasbeen suggested to play a crucial role in major depressive disorder. However, norepinephrine transporter availability in major depressive disorder and its role with clinical symptoms are not known. The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms. Method: The present research was a cross-sectional study in which 19 patients with major depressive disorder and 19 age- and sex-matched healthy comparison subjects underwent positron emission tomography scanning to evaluate the norepinephrine transporter availability measured by the radioligand (S,S)-[18F]FMeNER-D2. Norepinephrine transporter availability in the thalamus and its subregions was quantified in terms of nondisplaceable binding potential (BPND). The authors also analyzed the association between norepinephrine transporter availability and clinical symptoms. Results: Compared with healthy subjects, patients with major depressive disorder showed 29.0{\%} higher BPND values in the thalamus and, in particular, 28.2{\%} higher values in the thalamic subregion anatomically connected to the prefrontal cortex. Elevated norepinephrine transporter availability in the thalamus in patients was positively correlated with attention, as measured by the Trail Making Test, part A. Conclusions: These findings revealed altered norepinephrine transmission in patients with major depressive disorder, suggesting that this alteration could be related to attention in this patient population.",
author = "Sho Moriguchi and Makiko Yamada and Harumasa Takano and Tomohisa Nagashima and Keisuke Takahata and Keita Yokokawa and Takehito Ito and Tatsuya Ishii and Yasuyuki Kimura and Zhang, {Ming Rong} and Masaru Mimura and Tetsuya Suhara",
year = "2017",
month = "1",
day = "1",
doi = "10.1176/appi.ajp.2016.15101334",
language = "English",
volume = "174",
pages = "36--41",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "1",

}

TY - JOUR

T1 - Norepinephrine transporter in major depressive disorder

T2 - A PET study

AU - Moriguchi, Sho

AU - Yamada, Makiko

AU - Takano, Harumasa

AU - Nagashima, Tomohisa

AU - Takahata, Keisuke

AU - Yokokawa, Keita

AU - Ito, Takehito

AU - Ishii, Tatsuya

AU - Kimura, Yasuyuki

AU - Zhang, Ming Rong

AU - Mimura, Masaru

AU - Suhara, Tetsuya

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: The norepinephrine transporter hasbeen suggested to play a crucial role in major depressive disorder. However, norepinephrine transporter availability in major depressive disorder and its role with clinical symptoms are not known. The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms. Method: The present research was a cross-sectional study in which 19 patients with major depressive disorder and 19 age- and sex-matched healthy comparison subjects underwent positron emission tomography scanning to evaluate the norepinephrine transporter availability measured by the radioligand (S,S)-[18F]FMeNER-D2. Norepinephrine transporter availability in the thalamus and its subregions was quantified in terms of nondisplaceable binding potential (BPND). The authors also analyzed the association between norepinephrine transporter availability and clinical symptoms. Results: Compared with healthy subjects, patients with major depressive disorder showed 29.0% higher BPND values in the thalamus and, in particular, 28.2% higher values in the thalamic subregion anatomically connected to the prefrontal cortex. Elevated norepinephrine transporter availability in the thalamus in patients was positively correlated with attention, as measured by the Trail Making Test, part A. Conclusions: These findings revealed altered norepinephrine transmission in patients with major depressive disorder, suggesting that this alteration could be related to attention in this patient population.

AB - Objective: The norepinephrine transporter hasbeen suggested to play a crucial role in major depressive disorder. However, norepinephrine transporter availability in major depressive disorder and its role with clinical symptoms are not known. The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms. Method: The present research was a cross-sectional study in which 19 patients with major depressive disorder and 19 age- and sex-matched healthy comparison subjects underwent positron emission tomography scanning to evaluate the norepinephrine transporter availability measured by the radioligand (S,S)-[18F]FMeNER-D2. Norepinephrine transporter availability in the thalamus and its subregions was quantified in terms of nondisplaceable binding potential (BPND). The authors also analyzed the association between norepinephrine transporter availability and clinical symptoms. Results: Compared with healthy subjects, patients with major depressive disorder showed 29.0% higher BPND values in the thalamus and, in particular, 28.2% higher values in the thalamic subregion anatomically connected to the prefrontal cortex. Elevated norepinephrine transporter availability in the thalamus in patients was positively correlated with attention, as measured by the Trail Making Test, part A. Conclusions: These findings revealed altered norepinephrine transmission in patients with major depressive disorder, suggesting that this alteration could be related to attention in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=85008506351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008506351&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2016.15101334

DO - 10.1176/appi.ajp.2016.15101334

M3 - Article

C2 - 27631962

AN - SCOPUS:85008506351

VL - 174

SP - 36

EP - 41

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 1

ER -